An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS
暂无分享,去创建一个
R. Bejar | O. Abdel-Wahab | P. Greenberg | M. Figueroa | R. Majeti | C. Hourigan | N. Daver | D. Steensma | U. Borate | P. Fenaux | A. Wei | S. Nimer | S. Gore | H. Carraway | M. Sekeres | A. Brunner | S. Halene | E. Padron | A. Nazha | J. Boultwood | G. Roboz | U. Platzbecker | V. Santini | M. D. Della Porta | D. Starczynowski | J. Bewersdorf | A. Zeidan | G. Sanz | F. Efficace | R. Buckstein | A. List | Justin Taylor | S. Loghavi | R. Little | E. Griffiths | Mina L. Xu | J. Churpek | D. Sallman | R. Komrokji | R. Hasserjian | M. Savona | A. DeZern | Vijay Kuchroo | Zhuoer Xie | O. Odenike | M. Stahl | John M. Bennett | M. Patnaik | N. Kim | Tae Kon Kim
[1] A. Brunner,et al. Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS) , 2022, Blood Cancer Journal.
[2] B. Ebert,et al. Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. , 2022, Blood.
[3] M. Loh,et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. , 2022, Blood.
[4] Y. Natkunam,et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms , 2022, Leukemia.
[5] D. Faller,et al. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML , 2022, Blood advances.
[6] M. Jongen‐Lavrencic,et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome , 2022, Blood.
[7] R. Epstein,et al. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials? , 2021, Future oncology.
[8] M. Cazzola,et al. Relationship between clone metrics and clinical outcome in clonal cytopenia. , 2021, Blood.
[9] E. Estey,et al. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal , 2021, Blood.
[10] D. Pollyea,et al. The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses. , 2021, Blood reviews.
[11] J. Barnard,et al. Validation of International Working Group response criteria in higher‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium , 2020, Cancer medicine.
[12] J. Klco,et al. Advances in germline predisposition to acute leukaemias and myeloid neoplasms , 2020, Nature Reviews Cancer.
[13] Stuart M. Gardos,et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis , 2020, Nature Genetics.
[14] K. Pradhan,et al. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies , 2019, Nature Cell Biology.
[15] Y. Kluger,et al. A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies , 2018, Nature Communications.
[16] D. Steensma,et al. A call for action: Increasing enrollment of untreated patients with higher‐risk myelodysplastic syndromes in first‐line clinical trials , 2017, Cancer.
[17] M. Cazzola,et al. Clinical significance of somatic mutation in unexplained blood cytopenia. , 2017, Blood.
[18] C. Bloomfield,et al. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Broder,et al. The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail. , 2017, The oncologist.
[20] D. Neuberg,et al. Prognostic Mutations in Myelodysplastic Syndrome after Stem‐Cell Transplantation , 2017, The New England journal of medicine.
[21] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[22] J. Cleveland,et al. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. , 2016, Blood.
[23] S. Nahas,et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes , 2016, Leukemia.
[24] M. McCarthy,et al. Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.
[25] M. Stratton,et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.
[26] B. Esterni,et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. Issa,et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy , 2010, Cancer.
[28] H. Dombret,et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[30] B. Cheson,et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.